.

BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Citi
Mallinckrodt
Accenture
Federal Trade Commission
AstraZeneca
Covington
UBS
Teva
Healthtrust
McKesson

Generated: September 20, 2017

DrugPatentWatch Database Preview

Alitretinoin - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for alitretinoin and what is the scope of alitretinoin patent protection?

Alitretinoin
is the generic ingredient in one branded drug marketed by Eisai Inc and is included in one NDA. There is one patent protecting this compound. Additional information is available in the individual branded drug profile pages.

Alitretinoin has eighteen patent family members in eleven countries.

There are two drug master file entries for alitretinoin. One supplier is listed for this compound.

Summary for Generic Name: alitretinoin

Tradenames:1
Patents:1
Applicants:1
NDAs:1
Drug Master File Entries: see list2
Suppliers / Packagers: see list1
Bulk Api Vendors: see list28
Clinical Trials: see list16
Patent Applications: see list9,214
Therapeutic Class:Antineoplastics
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:alitretinoin at DailyMed

Pharmacology for Ingredient: alitretinoin

Ingredient-typeRetinoids
Drug ClassRetinoid
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Eisai Inc
PANRETIN
alitretinoin
GEL;TOPICAL020886-001Feb 2, 1999RXYesYes► Subscribe► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: alitretinoin

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Eisai Inc
PANRETIN
alitretinoin
GEL;TOPICAL020886-001Feb 2, 1999► Subscribe► Subscribe
Eisai Inc
PANRETIN
alitretinoin
GEL;TOPICAL020886-001Feb 2, 1999► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: alitretinoin

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,968,989 Means for the modulation of processes mediated by retinoid receptors and compounds useful therefor► Subscribe
7,056,954Means for the modulation of processes mediated by retinoid receptors and compounds useful therefor► Subscribe
6,992,108Means for the modulation of processes mediated by retinoid receptors and compounds useful therefor► Subscribe
6,576,676 Means for the modulation of processes mediated by retinold receptors and compounds useful therefor► Subscribe
6,506,917 Compounds and compositions useful for modulation of processes mediated by RXR► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: alitretinoin

Country Document Number Estimated Expiration
Germany617614► Subscribe
Denmark0617614► Subscribe
Japan4001618► Subscribe
European Patent Office0807624► Subscribe
JapanH08502238► Subscribe
Canada2123223► Subscribe
Austria439341► Subscribe
European Patent Office0617614► Subscribe
Japan2007254481► Subscribe
Australia679171► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: ALITRETINOIN

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
/2001Austria► SubscribePRODUCT NAME: ALITRETINOIN; REGISTRATION NO/DATE: EU/1/00/149/001 20001011
C/GB01/014United Kingdom► SubscribePRODUCT NAME: ALITRETINOIN; REGISTERED: UK EU/1/00/149/001 20001018
01/009Ireland► SubscribePRODUCT NAME: PANRETIN-ALITRETINOIN
00043Netherlands► SubscribePRODUCT NAME: ALITRETINOIN; NAT. REGISTRATION NO/DATE: EU/1/00/149/001 20001011; FIRST REGISTRATION: EU/1/00/149/001 20001011
2001 00012Denmark► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

McKesson
Accenture
Covington
AstraZeneca
Moodys
Johnson and Johnson
Chubb
UBS
US Department of Justice
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot